Anne‐Sofie Bjerrum
YOU?
Author Swipe
View article: Cumulative corticosteroid burden over twenty-five years in patients initiating biologic therapy for severe asthma – a nationwide cohort study
Cumulative corticosteroid burden over twenty-five years in patients initiating biologic therapy for severe asthma – a nationwide cohort study Open
Background Systemic corticosteroid use in severe asthma is associated with morbidity and mortality. Little is known about the long-term corticosteroid burden prior to biologic therapy. This study aims to estimate the cumulative corticoster…
View article: Financial burden of productivity loss in severe asthma and impact of biologic therapy
Financial burden of productivity loss in severe asthma and impact of biologic therapy Open
The financial burden of productivity loss in severe asthma is substantial, primarily due to presenteeism. Biologic therapy significantly enhances productivity, suggesting that much of the individual financial burden can be reversed.
View article: Biologic Prescription Patterns and Biomarker Determinants of First‐Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis
Biologic Prescription Patterns and Biomarker Determinants of First‐Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis Open
Background Asthma and atopic dermatitis are common type‐2 (T2)‐driven diseases that often coexist, although different T2 biomarkers indicate disease severity in each condition. Multiple biologics target T2 inflammation, but only dupilumab …
View article: Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register Open
View article: Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study
Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study Open
View article: The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma
The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma Open
Biologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.
View article: Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma Open
Background Biologics can induce remission in some patients with severe asthma; however, little is known about pre-biologic disease trajectories and their association with outcomes from biological treatment. We aimed to identify long-term t…
View article: Clinical Response and Remission in Patients Treated with Dupilumab for Severe Asthma Results from the Nationwide Danish Severe Asthma Register
Clinical Response and Remission in Patients Treated with Dupilumab for Severe Asthma Results from the Nationwide Danish Severe Asthma Register Open
View article: Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)
Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study) Open
Background Anti-interleukin (IL)-5 biologics effectively reduce exacerbations and the need for maintenance oral corticosteroids (mOCS) in severe eosinophilic asthma. However, it is unknown how long anti-IL-5 treatment should be continued. …
View article: Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”
Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry” Open
View article: Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies Open
View article: Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register
Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register Open
Former smoking history and lifetime tobacco exposure do not have an impact on the efficacy of biologics in patients with severe asthma.
View article: Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry Open
View article: Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register
Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register Open
Background Phase III regulatory trials show that anti-interleukin (IL)-5 biologics efficiently reduce exacerbations and the use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligi…
View article: The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy
The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy Open
No abstract available